

Genome editing methods for *Bacillus subtilis*

Katherine J. Wozniak and Lyle A. Simmons*

Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, MI 48109

*To whom correspondence should be addressed: Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, Michigan 48109-1055, United States. Phone: (734) 647-2016, Fax: (734) 615-6337. E-mail: lasimm@umich.edu

1 **Abstract**

2 *Bacillus subtilis* is a widely studied Gram-positive bacterium that serves as an important model for
3 understanding processes critical for several areas of biology including biotechnology and human
4 health. *B. subtilis* has several advantages as a model organism: it is easily grown under laboratory
5 conditions, it has a rapid doubling time, it is relatively inexpensive to maintain, and it is non-pathogenic.
6 Over the last 50 years, advancements in genetic engineering and genetic manipulation have continued
7 to make *B. subtilis* a genetic workhorse in scientific discovery. In this chapter, we describe methods for
8 traditional gene disruption, use of gene deletion libraries from the Bacillus Genetic Stock Center, allelic
9 exchange, CRISPRi, and CRISPR/Cas9. Additionally, we provide general materials and equipment
10 needed, strengths and limitations, time considerations, and troubleshooting notes to perform each
11 method. Use of the methods outlined in this chapter will allow researchers to create gene insertions,
12 deletions, substitutions, and RNA interference strains through a variety of methods custom to each
13 application.

14

15 **Key words:** CRISPR/Cas9, genetic manipulation, *Bacillus subtilis*, genetic engineering, Gram-positive

16

17 **1. Introduction**

18 The Gram-positive model bacterium *Bacillus subtilis* is a highly tractable genetic system, and is often
19 more straightforward to manipulate than human pathogens or environmental bacterial isolates from the
20 same phylum. The numerous genetic tools available, the development of genetic competence, and rapid
21 growth rate are a few attributes that have maintained *B. subtilis* as a model organism for studying a wide
22 variety of conserved biological processes.

23 *B. subtilis* can be easily grown under conditions that activate the development of genetic competence for
24 the uptake of exogenous DNA in the laboratory with limited media, tools, and expense [1]. After growing
25 *B. subtilis* to stationary phase in minimal media, cells induce a genetic program for natural competence
26 allowing for the uptake and integration of extracellular DNA or the uptake, reassembly, and maintenance
27 of plasmids [2]. Growth into stationary phases induces expression of the global competence regulator
28 ComK, which in turn activates expression of the ComK regulon including genes for DNA uptake, and

29 homologous recombination [3-6]. Once *B. subtilis* cells non-specifically bind DNA, the transforming DNA
30 is fed through a channel where it enters the cytosol as single stranded DNA (ssDNA) [[7] for review [8]].
31 When incoming DNA has sequence homology with the chromosome, RecA catalyzes homology search
32 and pairing with the *B. subtilis* chromosome [9]. For comprehensive reviews on the mechanism of natural
33 competence and DNA repair, we direct readers to the following reviews [10,8,11,12]. Harnessing the
34 natural competency of *B. subtilis* has led to many methods for genetic manipulation, with several new
35 advances occurring within the last 12 years [13-16]. In addition to natural competence, *B. subtilis* has an
36 efficient homologous recombination system allowing for straightforward and effective genetic alterations
37 to be built using PCR fragments, plasmids, or genomic DNA [1]. For efficient homologous recombination
38 to occur, template DNA should contain approximately 500 bp of homology to the host chromosome. It is
39 important for users to consider the order of gene deletion and the method of integration used when
40 studying mutant alleles in processes that are dependent on or affected by competence and
41 recombination because integration of transforming DNA uses both the genetic competence and
42 homologous recombination machinery.

43 There are a number of tools readily available to *B. subtilis* researchers (**Figure 1**). A deletion library
44 containing erythromycin and kanamycin cassette interruptions of non-essential genes and a library
45 containing CRISPR-interference (CRISPRi) strains of essential genes are housed at the Bacillus Genetic
46 Stock Center (<http://www.bgsc.org>) (**Figure 2**). These resources are available for integration of knockout
47 alleles or to knockdown essential genes [14,16]. Once strains are acquired, researchers can extract
48 genomic DNA (gDNA) and use it to transform their strain background of interest [14]. Double and triple
49 knockouts can be achieved using this method (discussed in the next section). CRISPRi strains contain a
50 single guide RNA (sgRNA) for Cas9 targeting to the chromosomal gene of interest, resulting in RNA
51 polymerase stalling and an inhibition of transcription [16]. The level of gene transcription can also be
52 titrated using CRISPRi, reducing expression to exceptionally low levels without completely eliminating
53 gene function [16]. CRISPRi is beneficial for the study of essential genes or genes that require a
54 conditional knockdown in transcription to examine the resulting phenotype [16].

55 Markerless mutations in *B. subtilis* can be achieved using several different methods [14,17,13,15]. To
56 create a deletion using the *Bacillus* gene knockout library, pDR244 aids in the removal of antibiotic
57 insertions. The plasmid pDR244 contains a temperature-sensitive origin of replication and constitutively
58 expresses Cre recombinase [14]. Cre recognizes *lox* sites flanking an integrated antibiotic cassette in
59 strains from the *Bacillus* Genetic Stock Center library, allowing for excision of the antibiotic cassettes
60 leaving only a *lox* scar [14] (**Figure 2**). A second approach involves the integration and looping out of the
61 pMiniMad plasmid carrying the desired genetic change. The integration vector pMiniMad uses a
62 temperature-sensitive origin of replication to create a markerless change. Cells transformed with
63 pMiniMad are passaged at the non-permissive temperature to encourage a single crossover event in the
64 host genome, conferring erythromycin resistance [15,17]. Once transformants are switched to the
65 permissive temperature, the plasmid excises from the host genome resulting in erythromycin sensitivity
66 [14]. This method also allows for the markerless integration of point mutations, insertions, or deletions.
67 The third and most recent advance in genetic engineering methods is the use of CRISPR/Cas9 in *B.*
68 *subtilis* [18,13]. CRISPR/Cas9 allows researchers to make clean substitutions, deletions, and insertions
69 in multiple backgrounds with high efficiency [18,13]. In addition to efficiency, the CRISPR/Cas9 system
70 allows for the insertion or deletion of large fragments on the order of 20 kb [18,13]. Although
71 CRISPR/Cas9 requires more materials than the other methods described above, plasmids engineered
72 for one alteration are easily adapted for the introduction of other genetic manipulations.
73 The aim of this chapter is to provide an in-depth series of methods that will enable researchers to
74 perform genetic manipulation of several different strains of *B. subtilis*. We describe five methods for
75 genetic engineering: 1. Traditional gene manipulation, 2. Use of the deletion library, 3. pMiniMad for
76 allelic exchange, 4. CRISPRi, and 5. CRISPR/Cas9. Below, we also provide the resources and protocols
77 for each recombineering method described.

78 **2. Materials:**

79 **2.1 Reagents**

80 1. Luria-Bertani (LB) medium: 10 g NaCl, 10 g tryptone, 5 g yeast extract in 1 L H₂O.
81 Autoclave to sterilize.

82 2. Luria-Bertani (LB) agar plates: 10 g NaCl, 10 g tryptone, 5 g yeast extract, 15 g agar in 1 L
83 H₂O. Autoclave to sterilize and pour into sterile Petri plates once the mixture cools to
84 60°C. If antibiotics are required, add when the mixture reaches 60°C and mix thoroughly.
85 3. LB + starch plates: 1L LB medium, 10 g/L corn starch, 15 g agar. Autoclave to sterilize.
86 Pour ~20 mL into sterile Petri plates once the solution has reached 60°C.
87 4. LM medium: LB medium supplemented with 3 mM MgSO₄.
88 5. PC buffer (10X): 107 g/L potassium hydrate phosphate (anhydrous), 174.2 g/L potassium
89 dihydrate phosphate (anhydrous), 10 g/L trisodium citrate (pentahydrate), up to 1 L H₂O.
90 Filter sterilize.
91 6. MD medium: 1X PC buffer, 50% w/v glucose, 10 mg/mL L-tryptophan, 2.2 g/mL ferric
92 ammonium citrate, 100 mg/mL potassium aspartate, 1M MgSO₄, 10 mg/mL
93 phenylalanine. Store protected from light at 4°C.
94 7. Iodide solution: 0.5 g iodine, 5.0 g potassium iodide in 100 mL H₂O. Store protected from
95 light at 4°C.
96 8. 0.5 µg/mL erythromycin for *B. subtilis*
97 9. 5 µg/mL chloramphenicol for *B. subtilis*
98 10. 100 µg/mL spectinomycin for *B. subtilis*
99 11. 100 µg/mL ampicillin for *E. coli*
100 12. Sterile saline: 0.85% NaCl in H₂O, or phosphate-buffered saline (137 mM NaCl, 2.7 mM
101 KCl, 10 mM Na₂HPO₄, 1.8 mM KH₂PO₄; adjust the pH to 7.4 using HCl)
102 13. 50% glycerol
103 14. Molecular grade agarose (to make 0.5-1% final agarose gels for genotyping and
104 purification of amplicons for cloning).
105 15. 50X TAE buffer: 242 g Tris base, 57.1 ml glacial acetic acid, 100 ml EDTA (pH 8.0), H₂O
106 to 1 L.
107 16. PCR reagents (Taq polymerase for genotyping, High fidelity polymerase for Sanger
108 Sequencing, dNTPs, buffer, nuclease-free H₂O)
109 17. MC1061 competent *E. coli* cells or another competent cell line
110 18. Bsal-HF
111 19. Cutsmart buffer (NEB)
112 20. T₄ DNA ligase
113 21. Calf intestinal phosphatase (CIP)
114 22. T₄ polynucleotide kinase (PNK)
115 23. TOP10 or equivalent competent *E. coli* cells
116 24. gDNA or PCR amplified DNA for construct creation
117 25. pMiniMad
118 26. pDR244
119 27. pPB41 or pPB105
120 28. Genotyping primers are specific to the user and flank the locus of interest
121 29. Optional: genotyping primers flanking *amyE* and/or *lacA* to confirm insertion
122 a. *amyE*: 5'- TTCTTCGCTTGGCTGAAAAT-3' (forward), 5'-
123 CACCAGGTTTTGGTTGCT-3' (reverse)
124 b. *lacA*: 5'- TAGACGAAAGCGCCAAGATT-3' (forward), 5'-
125 CTGGCGTTTCCGTTGTAT-3' (reverse)
126 30. Primers compatible with pPB41 [13]:
127 a. oPEB217: 5'-GAACCTCATTACGAATTTCAGCATGC-3'
128 b. oPEB218: 5'-GAATGGCGATTTCGTTCGTGAATAC-3'
129 31. Primers compatible with CRISPR/Cas9 [13]:
130 a. oPEB232: 5'-GCTGTAGGCATAGGGCTTGGTTATG-3'
131 b. oPEB234: 5'-GTATTCACGAACGAAAATGCCATTCTAGCAGCACG
132 CCATAGTGACTG-3'

133 **2.2 General Equipment**

134 1. 2 mL cryogenic screw top tubes for glycerol stocks
135 2. Round bottom plastic tubes (14 mL) or glass tubes
136 3. Wooden sticks or sterile loops for picking colonies
137 4. Shaking incubator at 37°C
138 5. Shaking incubator at 25°C
139 6. Stationary incubator at 37°C
140 7. Stationary incubator at 42°C
141 8. Heat block at 65°C (see method 3.4)
142 9. Thermocycler
143 10. Gel electrophoresis apparatus
144 11. Sterile spreaders (glass beads, glass or plastic serological pipettes)
145 12. PCR tubes

146

147 **3. Methods:**

148 3.1. Traditional gene manipulation (2-day protocol)

149 **3.1.1. Templates & genotyping primers**

150 *B. subtilis* can undergo a double crossover event with DNA containing 100 bp to 500 bp (or more)
151 flanking the site of exchange. The template can be plasmid-based, a PCR fragment, or genomic DNA
152 with a selectable marker. For plasmid-based templates, there should be a site of recombination within it
153 (can be the native or ectopic locus). For integration at an ectopic locus, we frequently use the non-
154 essential gene *amyE* coding for starch utilization [19] or *lacA* coding for β-galactosidase [20]. Many
155 different integration vectors using the *amyE* or *lacA* loci are readily available from the Bacillus Genetic
156 Stock Center (http://www.bpsc.org/_catalogs/Catpart4.pdf). These plasmids and methods described
157 below can be used for a variety of *B. subtilis* strains including JH642, PY79 and NCIB 3610 with a
158 deletion of a competence inhibitor *comI* [21]. Other strain backgrounds can also be found at the Bacillus
159 Genetic Stock Center. To create and confirm the desired strain in 2-3 days (after preparing the template),
160 be sure to order genotyping primers specific to the locus of interest before beginning the competency
161 and transformation protocols. Genotyping primers are used to amplify the locus of interest to easily
162 detect insertions or deletions.

163 **3.1.2. Making *B. subtilis* competent in a laboratory setting & transformation**

164 We recommend making *B. subtilis* competent each time a transformation is desired. For some protocols
165 it is standard to freeze stocks of competent *Bacillus subtilis* using 20% glycerol, however we prefer
166 freshly prepared competent cells because they are often transformed more efficiently.

167 1. Streak plates from glycerol or DMSO stocks containing the strain to be manipulated and grow at 30-
168 37°C for 16 hours.

169 2. Inoculate 2 mL LM medium (LB supplemented with 3 mM MgSO₄) with a single colony in a 14 mL
170 round bottom tube and grow with shaking (200 rpm) for 3 hours at 37°C (until OD₆₀₀~1). See note 1a.

171 3. Using sterile technique, transfer 20 µL of the LM culture to 500 µL MD medium in a test tube and grow
172 for 4 hours at 37°C to reach stationary phase. See note 1b.

173 4. Add 1-5 µL of template DNA to turbid MD cultures (up to 100 ng) and let grow for 90 minutes at 37°C.
174 Pre-dry antibiotic plates during this time to help with absorption of liquid.

175 5. Transfer 200 µL of turbid MD cells containing DNA onto respective antibiotic containing plates and
176 spread until completely dry using sterile glass beads or glass serological pipettes. See note 2.

177 **3.1.3. Genotyping & storing transformants**

178 1. After ~16 hours of transformation plate incubation, visible colonies will start to form. For clones with
179 multiple antibiotic resistances, this could take 24-48 hours. See note 1c.

180 2. Restreak at least 8 transformations for isolation on fresh antibiotic-containing plates and grow
181 overnight at 30-37°C. Restreaking of single colonies should be done at least twice. Try to pick a variety
182 of colony sizes from different plate locations.

183 3. Perform colony PCR on *B. subtilis* colonies that grew following restreak on antibiotic(s). See notes 3-4.

184 4. Grow positive transformants in LB with respective antibiotics for 4-6 hours at 30°C or 37°C for glycerol
185 or DMSO stock preparation followed by storage at -80°C.

186 5. Add culture with up to 25% glycerol or 10% DMSO to screw top cryogenic tubes and freeze indefinitely
187 at -80°C.

188 **3.1.4. Considerations**

189 Strengths: After designing appropriate templates, positive transformants are achieved in 2 days. Media
190 can be made in-house.

191 Limitations: Genetic manipulations using genomic DNA (gDNA) as the template need to be distant
192 (~100,000 bp), or the risk of the WT copy recombining and replacing the altered locus is high, requiring
193 further screening to obtain the correct genotype. All templates using this method rely on antibiotic
194 selection to isolate transformants. When using gDNA, perform DNA dilutions to limit the likelihood for
195 transformation and integration of nonlabelled loci by congression (for more information please see [1]).

196 3.2: Deletion library (available through the Bacillus Genetic Stock Center)

197 **3.2.1. History and mechanism of deletion library strains & pDR244**

198 Koo *et al.* created a library of erythromycin (BKE) and kanamycin (BKK) single gene interruptions in *B.*
199 *subtilis* 168, consisting of 3,968 and 3,970 genes, respectively [14]. These stable, complete libraries
200 allow for creation of multiple mutants with antibiotic markers that can be easily removed by plasmid-
201 borne Cre recombinase driven from pDR244 [14]. Antibiotic cassettes are flanked by *lox66* and *lox71*
202 sites, which are acted on by Cre recombinase at permissive temperatures to excise the flanked cassette
203 and create a *lox* scar [14]. Plasmid pDR244 is easily cured from cells following incubation at the non-
204 permissive temperature, resulting in cells without antibiotic resistance and a clean deletion flanked by a
205 *lox* scar [14]. The double mutant *lox72* scar is reduced for Cre binding ability, allowing for multiple
206 mutations to be made in the same background [23]. Additionally, the antibiotic cassettes lack a
207 transcriptional terminator to reduce the likelihood of polar effects on downstream genes in an operon
208 [14].

209 **3.2.2. Competency, transformation, & recovery**

210 If attempting recombination at a single locus from the deletion library, all protocol elements are the same
211 as in section 3.1.2. The DNA template would be gDNA from a strain obtained from the stock center with
212 the desired change. When making multiple mutations dependent on a single antibiotic resistance
213 cassette, integrate constructs sequentially. For example, transform *B. subtilis* with gDNA for one locus,
214 screen, and make cryogenic stocks for each isolate. Next, remove the antibiotic resistance cassette from
215 the newly created strain using pDR244. After confirmation, make competent cells from the deletion strain
216 and transform with gDNA again and repeat the process. If moving markers from a different genetic
217 background, check all available auxotrophic markers or other genetic markers in the newly created
218 strain.

219 **3.2.3. Use of pDR244 to create a *loxP*-flanked clean deletion (4-day protocol)**

220 1. Streak cells onto plates from glycerol or DMSO stocks containing the strain to be engineered and grow
221 at 30-37°C for 16 hours (day 1).

222 2. Inoculate 2 mL LM media (LB supplemented with 3 mM MgSO₄) with a single colony in a 14 mL round
223 bottom tube and grow with shaking (200 rpm) for 3 hours at 37°C (until OD₆₀₀~1). See note 1a.

224 3. Transfer 20 µL of the LM culture to 500 µL MD medium in a test tube and grow for 4 hours at 37°C to
225 reach stationary phase. See note 1b.

226 4. Add 1-2 µL of pDR244 (up to 100 ng total) to 500 µL of cells from MD tubes and let grow for 90 minutes
227 at 37°C for transformation. Pre-dry antibiotic plates containing spectinomycin (selection for pDR244) and
228 the antibiotic within your gene interruption. See note 2.

229 5. Transfer 200 µL of transformation reaction onto plates containing spectinomycin and spread until
230 completely dry using sterile glass beads or glass serological pipettes.

231 **3.2.4. Screening & excising the antibiotic resistance cassette**

232 1. The next day (day 3), streak at least 8 transformants for isolation on spectinomycin plates and
233 incubate at 37°C for 16 hours. See note 1c.

234 2. Streak a single line onto a LB plate and grow at 42°C for 12 hours.

235 3. Streak a single line from the LB plate onto a new LB plate, and a plate containing
236 spectinomycin+antibiotic (erythromycin if using BKE strain or kanamycin if using BKK strain), and a third
237 plate containing antibiotic but lacking spectinomycin (in that order) and grow at 42°C overnight. See note
238 5.

239 4. The next day (day 4), assess growth on plates. Transformants containing clean deletions will have
240 grown on LB only. If there is still growth on spectinomycin+antibiotic (erm or kan), then pDR244 was not
241 cured. If there is growth on antibiotic only plates, the cassette remains interrupting the gene and has not
242 recombined out. See notes 3-4.

243 5. Grow culture & cryogenic stock as in method 1.

244 **3.2.5. Considerations**

245 Strengths: Gene interruption strains are available from the Bacillus Genetic Stock Center at the Ohio
246 State University. Once your order is placed, Dr. Zeigler will next-day ship your strains via UPS.

247 Limitations: The step-wise nature of making deletions takes >2 days.

248 3.3. pMiniMAD (6-day protocol)

249 **3.3.1. History and mechanism of pMiniMAD**

250 The pMiniMAD (also known as pMiniMAD2) plasmid was developed by Patrick & Kearns in 2008 for
251 allelic replacement [15]. The plasmid pMiniMAD contains a temperature sensitive origin of replication
252 (ColE1) and an ampicillin and erythromycin cassette [15]. In *E. coli*, the plasmid replicates at the
253 permissive temperature and can be selected for using ampicillin resistance. In *B. subtilis* at a non-
254 permissive temperature, a single crossover event will occur flanking the site of your choice and confer
255 erythromycin resistance. *B. subtilis* transformants are subsequently grown without erythromycin at the
256 permissive temperature, causing the plasmid to replicate and excise from the genome [15]. The result is
257 markerless allelic replacement in your desired *B. subtilis* strain. An *E. coli* strain containing the
258 pMiniMAD plasmid is available at the Bacillus Genetic Stock Center (strain ECE765). Around-the-world
259 PCR amplification [24] of the plasmid can be done using only one primer set, allowing for easy ligation of
260 your desired gene to create the full plasmid [15].

261 **3.3.2. Competency & transformation**

262 1. The protocol for making competent cells and transformation is the same as in section 3.1.2 (steps 1-
263 5). See note 1.

264 2. After plating transformants on erythromycin (section 3.1.2, step 5), grow at 37°C overnight (day 1).

265 See note 2.

266 **3.2.3. Recovery & screening**

267 1. Pick 4 colonies from transformation plates and use to inoculate 3 mL each of LB. Incubate for 10 hours
268 at 25°C (day 2).

269 2. Inoculate 30 μ L of each culture (may not be visibly turbid, this is OK to continue with) into 3 mL of
270 fresh LB and incubate at 25°C overnight.

271 3. The next day (day 3), repeat steps 1 & 2.

272 4. Inoculate 30 μ L of cultures again into 3 mL each of fresh LB. Grow at 37°C for ~3 hours (day 4).

273 5. Once the cultures reach OD₆₀₀ 1.1-1.3, perform 10-fold serial dilutions in sterile saline (10⁻⁴, 10⁻⁵, 10⁻⁶).

274 Spread 200 μ L of each dilution onto the respective LB plate. At the end of the day, let the plates grow
275 overnight at 37°C.

276 6. On day 5, identify which serial dilution for each culture results in the best isolation of individual
277 colonies per plate (approximately 20-80). From that dilution plate, select at least 12 transformants and
278 restreak for single colonies on LB and LB+erm. Grow overnight at 37°C.

279 7. The next day (day 6), assess which colonies were sensitive to erythromycin. Perform colony PCR on
280 these colonies to determine if the desired genetic changes is complete. See note 3 and 6.

281 8. Grow transformants in LB at 37°C for glycerol or DMSO stocks. Sanger Sequence the PCR product of
282 the region of interest from each strain to ensuring the nucleotide substitution or other genetic change is
283 correct.

284 **3.3.4. Considerations**

285 Strengths: Creation of a construct without antibiotic resistance. pMiniMAD is easily changed and
286 available through the Bacillus Genetic Stock Center.

287 Limitations: Takes 6 days and requires constant passaging and screening of many colonies. This does
288 not work for essential genes or can be challenging for gene disruptions that cause a severe growth
289 phenotype.

290 3.4: CRISPRi (2-day protocol)

291 **3.4.1. History of CRISPRi and its application in *B. subtilis***

292 Peters *et al.*, 2016 created a library of essential gene knockdowns in *B. subtilis* using CRISPR
293 interference [16]. To perform CRISPRi, constructs have two alterations: *lacA::P_{xyI}-dCas9 (erm^R)* and
294 *amyE::P_{veg}-sgRNA(gene) (cm^R)*. The sgRNAs target the non-template strand [16]. P_{veg} drives expression

295 of the sgRNA to the gene of interest during vegetative growth. dCas9 is induced with xylose and upon
296 induction, binds the sgRNA, and blocks RNA polymerase from transcribing [16]. This method is important
297 to study *B. subtilis* because it provides a conditional knockout or knockdown of essential genes or genes
298 that cause a severe growth phenotype when disrupted or depleted.

299 **3.4.2. Competency, transformation, & screening**

300 1. Streak plates with glycerol or DMSO stocks containing the strain to be manipulated and grow at 30-
301 37°C for 16 hours.

302 2. Inoculate 2 mL LM medium (LB supplemented with 3 mM MgSO4) with a single colony in a 14 mL
303 round bottom tube and grow with shaking (200 rpm) for 3 hours at 37°C (until OD₆₀₀~1). See note 1a.

304 3. Transfer 20 µL of the LM culture to 500 µL MD medium in a test tube and grow for 4 hours at 37°C to
305 reach stationary phase. See note 1b.

306 4. Add 1-5 µL your template DNA to 500 µL of cells from MD tubes (up to 100 ng) and let grow for 90
307 minutes at 37°C & pre-dry antibiotic plates.

308 5. Transfer 200 µL of transformation reaction onto LB+cm+erm plates and spread until completely dry
309 using sterile glass beads, or sterile glass serological pipettes. See note 2.

310 6. After ~16 hours of transformation plate incubation, visible colonies will start to form. For constructs
311 with multiple antibiotic resistances, this could take 24 hours or longer.

312 7. Restreak at least 8 transformations for isolation on fresh antibiotic-containing plates and grow
313 overnight at 30-37°C. Try to pick a variety of colony sizes from different plate locations.

314 8. Perform colony PCR on isolates that grew following restreak on antibiotics at both the *amyE* and *lacA*
315 loci. See note 7.

316 9. Grow positive transformants in LB with chloramphenicol and erythromycin for 4-6 hours at 37°C for
317 subsequent glycerol or DMSO stock preparation.

318 10. Add culture with up to 25% glycerol or 10% DMSO to cryogenic screw-top tubes and freeze
319 indefinitely at -80°C.

320 **3.4.3. Use of newly constructed strains**

321 1. To test interference of your desired gene, we recommend titrating xylose at several different
322 concentrations (or percentages) on LB plates. Start in 10-fold increments and then fine-tune within the
323 increments based on your desired result. Alternatively, perform qPCR to measure transcript levels
324 quantitatively.

325 2. Be sure to keep both erythromycin and chloramphenicol in the media when you use the CRISPRi
326 strains.

327 **3.4.4. Considerations**

328 Strengths: This protocol is fast and includes essential genes. The researcher can fine tune the level of
329 transcript by carefully modulating gene expression.

330 Limitations: The desired titration amount is up to the researcher and is determined experimentally.
331 Starting concentrations are usually 0.5% or 1% xylose (w/v). In addition, there are two antibiotic
332 cassettes and integrations for a single CRISPRi strain.

333 3.5: CRISPR/Cas9 (2-day protocol)

334 **3.5.1. History of CRISPR/Cas9 manipulation of genes in *B. subtilis***

335 With the recent application of CRISPR/Cas9 to create mutations in many organisms, an efficient protocol
336 was established for manipulation of *B. subtilis* by Burby and Simmons [18,13]. CRISPR/Cas9 allows the
337 user to make deletions, fusions, and point mutations in multiple backgrounds. The plasmids required for
338 this procedure are available at the Bacillus Genetic Stock Center [18,13]. The editing plasmids pPB41
339 (Spec^R & Amp^R) or pPB105 (Cm^R & Amp^R) are modified to insert a proto-spacer sequence to target the
340 locus of interest [18,13]. The second modification of pPB41 serves as the editing DNA template for
341 introduction into the genome [18,13]. After constructing both pieces of pPB41 using standard molecular
342 biology methods, the final editing plasmid is assembled. In short, the plasmid backbone containing
343 antibiotic resistance, editing template, Cas9, and protospacer sequences are ligated using Gibson
344 Assembly [22] to create one final plasmid. The resulting plasmid can be used to transform *B. subtilis* to
345 introduce the desired genetic change and is subsequently cured from cells with ease [13].

346 **3.5.2. Protocol for creating plasmid with proto-spacer for CRISPR/Cas9 alteration**

347 1. Digest pPB41 or pPB105 with restriction endonuclease *BsaI*.

348 2. Construct a phosphorylated proto-spacer for insertion into pPB41 or pPB105.

349 3. Ligate plasmid and proto-spacer together, transform *E. coli*, and isolate plasmid.

350 **3.5.3. Protocol for creating editing plasmid**

351 1. Use oPEB217 and oPEB218 with Q5 DNA polymerase to linearize pPB41. Gel extract and purify PCR
352 product.

353 2. Use oPEB232 and oPEB234 with Q5 DNA polymerase to PCR amplify CRISPR/Cas9 from plasmid
354 created in step 1. Gel extract and purify PCR product.

355 3. PCR amplify editing template, gel extract and purify.

356 4. Assemble full editing plasmid using Gibson Assembly.

357

358 **3.5.4. Transformation of plasmids and screening of transformants**

359 1. Make desired *B. subtilis* strain competent using Method 3.1.2.

360 2. After incubation in MD culture, add 200-600 ng of editing plasmid DNA and incubate for 60-90 minutes
361 at 37°C.

362 3. Plate 200 µL transformants on LB+spec and incubate at 30°C overnight.

363 4. Restreak single colonies on LB+spec for purity.

364 5. Cure isolates of plasmid by restreaking on LB for single colonies and incubating overnight at 45°C.

365 6. Screen isolates for plasmid loss by restreaking single colonies onto LB and LB+spec and incubate
366 again overnight at 45°C. There should be no growth on LB+spec plates if cells are cured of the plasmid.

367 7. Use genotyping primers to confirm alteration of interest.

368 **3.5.5. Considerations**

369 Strengths: It is possible to introduce multiple mutations of your own design in many different
370 backgrounds with high efficiency (80-100% positive clones). This method lacks antibiotic cassettes or
371 remnants of vector DNA used during cloning.

372 Limitations: Mutations are contingent upon a proto-spacer adjacent motif (PAM) sequence, NGG in *B.*
373 *subtilis*, near to the desired locus and requires more reagents than the other methods.

374 **4. Notes**

375 **1.** On competency and transformation: a. Glass or plastic tubes both work well for incubation of cells for
376 transformation; be sure the culture takes up 1/10 or less of the container volume for proper aeration.
377 Shaking incubation can be performed in a test tube rack in a warm room, water bath, or a rolling rack
378 within an incubator. b. Prepare MD tube for each transformation. c. If initial transformation of *B. subtilis*
379 with DNA is unsuccessful or for strains that grow more slowly due to other genetic changes, increasing
380 the incubation in LM media could be extended from 4 hours to ~6 hours, and incubation with gDNA could
381 be increased from 90 minutes to 3 hours.

382 **2.** On plating transformations: Pre-drying plates before spreading transformation mix is important to help
383 the liquid absorb into the plate for growth of single transformant colonies. Any remaining transformation
384 culture can be spread onto another plate (as is or diluted with MD medium to make 1:2, 1:5, and/or 1:10
385 dilutions).

386 **3.** On confirmation of transformants: Use genotyping primers to confirm correct amplicon size of
387 transformants. It is recommended to submit samples for Sanger Sequencing when making substitutions
388 or piecing together constructs using Gibson Assembly [22]. If using the *amyE* locus, add up to 1 mL
389 iodide solution to starch plate “patch” restreaks. If the gene is disrupted, and your construct was
390 successfully inserted, you will no longer see a starch clearing or “halo” around the patch. Please note
391 that iodide treatment is lethal to the cells on the starch plate.

392 **4.** On ensuring a double crossover event with exogenous DNA (method 1): Homology between the
393 desired *B. subtilis* locus and amplicon DNA will help increase likelihood of recombination. If homology is
394 sufficient and transformation is unsuccessful, titrating the amount of amplicon DNA in the transformation
395 could lead to the desired recombination event.

396 **5.** Notes on curing an antibiotic resistance marker using pDR244 (method 2): It is not necessary to go
397 back to the original LB streak when streaking plates containing antibiotics to assess if pDR244 has been
398 cured. Simply collect some bacteria from the first plate and continue streaking a single line on all plates.
399 Due to the high cell density of bacteria from the original plate during patch plating, there are still enough
400 cells to streak on the last plate of the series.

401 6. On increasing the number of markerless desired clones (method 3): After transformation and
402 integration of pMiniMad, passaging >4 cultures through room temperature incubations and screening >12
403 colonies from each could allow the researcher to find additional clones.

404 7. On CRISPRi (method 4): As the guide RNA is driven by a promoter inserted at *amyE*, streak a single
405 line onto LB plates containing 10 g/L starch to ensure this locus has been disrupted. Streak WT as a
406 control and incubate with the other antibiotic plates. Use genotyping primers to confirm correct amplicon
407 size of transformants. To determine if the *amyE* locus is disrupted, add up to 1 mL iodide solution to
408 starch plate streaks. You will no longer see a starch clearing or “halo” if the insertion at *amyE* occurred.

409 **5. References**

- 410 1. Hardwood CR, Cutting SM (1990) Molecular Biological Methods for *Bacillus*. John Wiley & Sons, Chichester Pages 1-35
- 411 2. Dubnau D (1991) Genetic competence in *Bacillus subtilis*. *Microbiol Rev* 55 (3):395-424
- 412 3. van Sinderen D, Luttinger A, Kong L, Dubnau D, Venema G, Hamoen L (1995) *comK* encodes the competence transcription factor, the key regulatory protein for competence development in *Bacillus subtilis*. *Molecular microbiology* 15 (3):455-462
- 413 4. van Sinderen D, ten Berge A, Hayema BJ, Hamoen L, Venema G (1994) Molecular cloning and sequence of *comK*, a gene required for genetic competence in *Bacillus subtilis*. *Molecular microbiology* 11 (4):695-703
- 414 5. Hamoen LW, Hajjema B, Bijlsma JJ, Venema G, Lovett CM (2001) The *Bacillus subtilis* competence transcription factor, ComK, overrides LexA-imposed transcriptional inhibition without physically displacing LexA. *J Biol Chem* 276 (46):42901-42907
- 415 6. Ogura M, Yamaguchi H, Kobayashi K, Ogasawara N, Fujita Y, Tanaka T (2002) Whole-genome analysis of genes regulated by the *Bacillus subtilis* competence transcription factor ComK. *J Bacteriol* 184 (9):2344-2351
- 416 7. Hahn J, Maier B, Hajjema BJ, Sheetz M, Dubnau D (2005) Transformation proteins and DNA uptake localize to the cell poles in *Bacillus subtilis*. *Cell* 122 (1):59-71. doi:10.1016/j.cell.2005.04.035
- 417 8. Dubnau D, Blokesch M (2019) Mechanisms of DNA Uptake by Naturally Competent Bacteria. *Annu Rev Genet* 53:217-237. doi:10.1146/annurev-genet-112618-043641
- 418 9. Yadav T, Carrasco B, Myers AR, George NP, Keck JL, Alonso JC (2012) Genetic recombination in *Bacillus subtilis*: a division of labor between two single-strand DNA-binding proteins. *Nucleic Acids Res* 40 (12):5546-5559. doi:10.1093/nar/gks173
- 419 10. Dubnau D, Provvedi R (2000) Internalizing DNA. *Res Microbiol* 151 (6):475-480. doi:10.1016/s0923-2508(00)00166-2
- 420 11. Lenhart JS, Schroeder JW, Walsh BW, Simmons LA (2012) DNA Repair and Genome Maintenance in *Bacillus subtilis*. *Microbiology and molecular biology reviews : MMBR* 76 (3):530-564. doi:10.1128/MMBR.05020-11
- 421 12. Ayora S, Carrasco B, Cardenas PP, Cesar CE, Canas C, Yadav T, Marchisone C, Alonso JC (2011) Double-strand break repair in bacteria: a view from *Bacillus subtilis*. *FEMS Microbiol Rev* 35 (4):437-458. doi:10.1111/j.1574-6941.2011.00353.x
- 422 13. Burby PE, Simmons LA (2017) CRISPR/Cas9 Editing of the *Bacillus subtilis* Genome. *Bio Protoc* 7 (8). doi:10.21769/BioProtoc.2272
- 423 14. Koo BM, Kritikos G, Farelli JD, Todor H, Tong K, Kimsey H, Wapinski I, Galardini M, Cabal A, Peters JM, Hachmann AB, Rudner DZ, Allen KN, Typas A, Gross CA (2017) Construction and Analysis of Two Genome-Scale Deletion Libraries for *Bacillus subtilis*. *Cell Syst* 4 (3):291-305 e297. doi:10.1016/j.cels.2016.12.013

445 15. Patrick JE, Kearns DB (2008) MinJ (YvjD) is a topological determinant of cell division in *Bacillus*
446 *subtilis*. *Mol Microbiol* 70 (5):1166-1179

447 16. Peters JM, Colavin A, Shi H, Czarny TL, Larson MH, Wong S, Hawkins JS, Lu CHS, Koo BM, Marta
448 E, Shiver AL, Whitehead EH, Weissman JS, Brown ED, Qi LS, Huang KC, Gross CA (2016) A
449 Comprehensive, CRISPR-based Functional Analysis of Essential Genes in Bacteria. *Cell* 165 (6):1493-
450 1506. doi:10.1016/j.cell.2016.05.003

451 17. Cozy LM, Kearns DB (2010) Gene position in a long operon governs motility development in *Bacillus*
452 *subtilis*. *Mol Microbiol* 76 (2):273-285. doi:10.1111/j.1365-2958.2010.07112.x

453 18. Burby PE, Simmons LA (2016) MutS2 promotes homologous recombination in *Bacillus subtilis*. *J*
454 *Bacteriol*. doi:10.1128/JB.00682-16

455 19. Shimotsu H, Henner DJ (1986) Construction of a single-copy integration vector and its use in
456 analysis of regulation of the trp operon of *Bacillus subtilis*. *Gene* 43 (1-2):85-94. doi:10.1016/0378-
457 1119(86)90011-9

458 20. Hartl B, Wehrli W, Wiegert T, Homuth G, Schumann W (2001) Development of a new integration site
459 within the *Bacillus subtilis* chromosome and construction of compatible expression cassettes. *J Bacteriol*
460 183 (8):2696-2699

461 21. Konkol MA, Blair KM, Kearns DB (2013) Plasmid-encoded ComI inhibits competence in the ancestral
462 3610 strain of *Bacillus subtilis*. *J Bacteriol* 195 (18):4085-4093. doi:10.1128/JB.00696-13

463 22. Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA, 3rd, Smith HO (2009) Enzymatic
464 assembly of DNA molecules up to several hundred kilobases. *Nat Methods* 6 (5):343-345.
465 doi:10.1038/nmeth.1318

466 23. Yan X, Yu HJ, Hong Q, Li SP (2008) Cre/lox system and PCR-based genome engineering in *Bacillus*
467 *subtilis*. *Appl Environ Microbiol* 74 (17):5556-5562. doi:10.1128/AEM.01156-08

468 24. Liu H, Naismith JH (2008) An efficient one-step site-directed deletion, insertion, single and multiple-
469 site plasmid mutagenesis protocol. *BMC Biotechnol* 8:91. doi:10.1186/1472-6750-8-91

470

471 **Acknowledgements**

472 Work in the Simmons lab is funded by grants from the National Institutes of Health (R35GM131772) and
473 the National Science Foundation (MCB 1714539). KJW was funded in part by an NIH Cellular
474 Biotechnology Training Grant (T32 GM008353), a pre-doctoral fellowship from the National Science
475 Foundation (#DEG 1256260), and a Rackham Merit Fellowship from the University of Michigan. We
476 would like to thank the *Bacillus* Genetic Stock Center and the director, Dr. Daniel Zeigler for his
477 continued service to the *Bacillus* scientific community.


478


479 **Figure legends**

480 **Figure 1.** Recombination of DNA into the *B. subtilis* genome. **(A)** Recombination of PCR products, **(B)**
481 Recombination of genomic DNA containing an antibiotic cassette, **(C)** Recombination of genomic DNA
482 from the CRISPRi library.

483

484 **Figure 2.** Basic procedure for use of the Bacillus Genetic Stock Center deletion library. **(A)** Experimental
485 outline of *erm* cassette removal to create clean deletions using pDR244, **(B)** pDR244 action inside the
486 cell.



A**B****Day 1 & Day 2**